CHRONIC OBSTRUCTIVE PULMONARY DISEASE - EFFECT ON THE CLINICAL COURSE OF CARDIOVASCULAR DISEASES
Article Sidebar
Main Article Content
Аннотация:
Chronic obstructive pulmonary disease (COPD) is an independent nosological form, which is characterized by limitation of the air flow rate associated with the pathological inflammatory process in the lungs. This disease is one of the most common diseases in the world, its prevalence in different countries is from 6% to 26%. causes complications. Currently, special attention is paid to the study of OSOK risk factors, including urban air pollution, an increase in the amount of industrial dust, age, smoking, infectious diseases of the respiratory tract, their frequent exacerbations, obstructive lung. the condition of the disease is getting worse. In clinical practice, there are no standards for identifying comorbidities, treating physicians are not always focused on the search for concomitant pathology, which leads to late detection of cardiovascular pathology , as a result of which complications and mortality increase.
Article Details
Как цитировать:
Библиографические ссылки:
Șerban RC, Hadadi L, Șuș I, Lakatos EK, Demjen Z, Scridon A. Impact of chronic obstructive pulmonary disease on in-hospital morbidity and mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. International Journal of Cardiology. 2017; 243:437–42. DOI: 10.1016/j.ij-card.2017.05.0442.
Global Initiative for Chronic Obstructive Lung Disease 2021. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 Report . Available at: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf.
Averkov O.V., Duplyakov D.V., Gilyarov M.Yu., Novikova N.A., Shakhnovich R.M., Yakovlev A.N. i dr. Acute infarction of myocardium with podemoma segment ST electrocardiogrammy. Klinicheskie rekomendatsii 2020. Russian cardiology magazine. 251-310
Jatene T, Biering-Sørensen T, Nochioka K, Mangione FM, Han-sen KW, Sørensen R et al. Frequency of Cardiac Death and Stent Thrombosis in Patients with Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials). The American Journal of Cardiology. 2017 ;119 (1):14–9. DOI: 10.1016/j.amj-card.2016.09.013
.Zafiraki V.K., Kosmacheva E.D. The patient has ischemic heart disease and chronic obstructive pulmonary disease, and the era of endovascular interventions and coronary arteries. -M.-Krasnodar: Kubansky Gosudarstvennyy Meditsinsky University, 2019. -286p
Sand JMB, Leeming DJ, Byrjalsen I, Bihlet AR, Lange P, Tal-Singer R et al. High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD - results from the ECLIPSE study. Respiratory Research. 2016 ;17 (1):125. DOI: 10.1186/s12931-016-0440-6
Prokofeva T.V., Lipnitskaya E.A., Kuzmichev B.Yu., Polunina O.S., Voronina L.P., Polunina E.A. The effect of chronic obstructive disease on legkix na uroven homocysteinemii i sostoyanie koronarnyx soudov and bolnyx infarktom myokarda. Tuberculosis is a disease. 2019; 97(10):12-8
Maclay JD , McAllister DA, MacNee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology. 2007 ;12 (5):634–41. DOI: 10.1111/j.1440-1843.2007.01136.
Portillo K, Abad-Capa J, Ruiz-Manzano J. Enfermedad pulmonar ob-structiva crónica y ventrículo izquierdo. Archivos de Bronconeu-mologia. 2015 ;51 (5):227–34. DOI: 10.1016/j.arbres.2014.03.012
Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wou-ters EFM. Systemic Effects of Smoking. Chest. 2007 ;131 (5):1557–66.
Yawn BP , Keenan JM. COPD— The Primary Care Perspective: Addressing Epidemiology, Pathology, Diagnosis, Treatment of Smoking's Multiple Morbidities and the Patient's Perspective. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2007 ;4 (1):67–83. DOI: 10.1080/15412550601169562
Vanfleteren LEGW, Spruit MA, Groenen MTJ, Bruijnzeel PLB, Taib Z, Rutten EPA et al. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. European Respiratory Journal. 2014 ;43 (5):1306–15. DOI: 10.1183/09031936.0016931
Man SFP, Van Eeden S, Sin DD. Vascular Risk in Chronic Obstructive Pulmonary Disease: Role of Inflammation and Other Mediators. Canadian Journal of Cardiology. 2012 ;28 (6):653–61. DOI: 10.1016/j.cj-ca.2012.06.013
Rabinovich RA , MacNee W. Should we treat chronic obstructive pulmonary disease as a cardiovascular disease? Expert Review of Respiratory Medicine. 2015 ;9 (4):459–72. DOI: 10.1586/17476348.2015.1070099
Wang R, Li JY, Cao Z, Li Y. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Res-pyrology. 2013 ;18 (8):1244–8. DOI: 10.1111/resp.12143
Fimognari FL , Scarlata S, Conte ME, Incalzi RA. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2008;3(1):89–96. DOI : 10.2147/ copd . s 1401
Karoli N. A. , Borodkin A. V. , Rebrov A. P. Chronic heart failure of different genesis // Pulmonology. 2016. No. 26 (1). S. 38–45.
Wang Q. P. , Cao XZ , Wang X. D. et al. Utility of NTproBNP for identifying LV failure in patients with acute exacerbation of chronic bronchitis // PLoS One. 2013. No. 8 (1). P. 525–553.
Mirzaev, Rizamat Ziyadullaevich, Eleonora Negmatovna Tashkenbaeva, and Gulnora Alievna Abdieva. "PROGNOSTIChESKIE KLINIChESKIE MARKERY POChEChNOY NEDOSTATOChNOSTI PRI METABOLIChESKOM SYNDROME."Journal cardiorespiratornyx issledovaniy SI -2 (2022).
Tashkenbaeva Eleonora Negmatovna, Abdieva Gulnora Alievna Features of ischemic heart disease in association with climacteric cardiopathy // European scientific review. 2018. No. 3-4.